On the other hand, in the phase I/II CheckMate 040 study including 174 advanced HCCs with available PD-L1 status, a non-statistically significant difference was reported between PD-L1 positive and PD-L1 negative patients treated with nivolumab (26% versus 19% in PD-L1 positive and PD-L1 negative HCCs, respectively, by using a cut-off value of 1% of tumor cells) (42). This evidence concerns the gene CD274 and neoplasm.